Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Liquidia Technologies Inc (LQDA)

Liquidia Technologies Inc (LQDA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 75,504
  • Shares Outstanding, K 18,643
  • Annual Sales, $ 2,710 K
  • Annual Income, $ -53,140 K
  • 60-Month Beta 0.48
  • Price/Sales 28.44
  • Price/Cash Flow N/A
  • Price/Book 2.40

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.52
  • Number of Estimates 2
  • High Estimate -0.37
  • Low Estimate -0.66
  • Prior Year -0.84
  • Growth Rate Est. (year over year) +38.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.25 +24.62%
on 09/03/19
6.50 -37.69%
on 08/14/19
-2.57 (-38.82%)
since 08/13/19
3-Month
3.25 +24.62%
on 09/03/19
9.00 -55.00%
on 06/20/19
-4.67 (-53.56%)
since 06/13/19
52-Week
3.25 +24.62%
on 09/03/19
38.46 -89.47%
on 10/09/18
-15.41 (-79.19%)
since 09/13/18

Most Recent Stories

More News
Liquidia Technologies Appoints Industry Veteran Dr. Joanna Horobin to Board of Directors

Liquidia Technologies, Inc. (Nasdaq: LQDA) ("Liquidia" or the "Company"), a late-stage clinical biopharmaceutical company, today announced the appointment of Joanna Horobin, M.B., Ch.B., to the Company's...

LQDA : 4.05 (-1.94%)
Liquidia to Present at H.C. Wainwright Healthcare Conference

Liquidia Technologies, Inc. (Nasdaq: LQDA) ("Liquidia" or the "Company"), a late-stage clinical biopharmaceutical company, announced that Neal Fowler, Chief Executive Officer of Liquidia, will present...

LQDA : 4.05 (-1.94%)
Liquidia to Present at Wedbush PacGrow Healthcare Conference

Liquidia Technologies, Inc. (Nasdaq: LQDA) ("Liquidia" or the "Company"), a late-stage clinical biopharmaceutical company, announced that Neal Fowler, Chief Executive Officer of Liquidia, will present...

LQDA : 4.05 (-1.94%)
Liquidia Technologies Reports Second Quarter 2019 Financial Results and Provides Corporate Update

On Track for Planned New Drug Application (NDA) Submission for LIQ861 in Late 2019

LQDA : 4.05 (-1.94%)
Liquidia to Report Second Quarter 2019 Financial Results and Provide Corporate Update on August 8, 2019

Liquidia Technologies, Inc. (Nasdaq:LQDA) ("Liquidia"), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT...

LQDA : 4.05 (-1.94%)
Liquidia and GSK Restructure Collaboration Agreement

Liquidia Technologies, Inc. (Nasdaq: LQDA) ("Liquidia" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its...

LQDA : 4.05 (-1.94%)
Liquidia Announces Clinical Update on INSPIRE; Targeting NDA Filing for LIQ861 in Late 2019

Liquidia Technologies, Inc. (Nasdaq: LQDA) ("Liquidia"), a late-stage clinical biopharmaceutical company, today provided an update on the Phase 3 INSPIRE trial and development of LIQ861 for the treatment...

LQDA : 4.05 (-1.94%)
Liquidia to Present at Jefferies Healthcare Conference

Liquidia Technologies, Inc. (Nasdaq:LQDA) ("Liquidia"), a late-stage clinical biopharmaceutical company, announced that Neal Fowler, Chief Executive Officer of Liquidia, will present a company overview...

LQDA : 4.05 (-1.94%)
Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) International Conference 2019

Liquidia Technologies, Inc. (Nasdaq: LQDA) ("Liquidia"), a late-stage clinical biopharmaceutical company, today announced that Nicholas Hill, MD, Chief Pulmonary, Critical Care & Sleep Division, Professor...

LQDA : 4.05 (-1.94%)
Liquidia Technologies Reports First Quarter 2019 Financial Results and Provides Corporate Update

Recent Phase 3 Data Highlight Clinical Relevance of LIQ861 in Treating Pulmonary Arterial Hypertension

LQDA : 4.05 (-1.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade LQDA with:

Business Summary

Liquidia Technologies, Inc. is a late-stage clinical biopharmaceutical company. It focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. The company's product candidate consists of LIQ861 for the treatment of...

See More

Key Turning Points

2nd Resistance Point 4.54
1st Resistance Point 4.29
Last Price 4.05
1st Support Level 3.86
2nd Support Level 3.68

See More

52-Week High 38.46
Fibonacci 61.8% 25.01
Fibonacci 50% 20.85
Fibonacci 38.2% 16.70
Last Price 4.05
52-Week Low 3.25

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar